Skip to main content

Advertisement

SpringerLink
Log in

Preclinical Study of Pharmacological Properties of Doxorubicin-NPh

  • Published:
Bulletin of Experimental Biology and Medicine Aims and scope

Preclinical study of therapeutic properties of an innovative drug Doxorubicin-NPh (doxorubicin in the form of ultrafine suspension of phospholipid liposomes) in comparison with free doxorubicin (Doxorubicin-Teva) and protected doxorubicin (Caelyx) was performed on transplanted murine tumor models. All these drugs were efficient in Ca755 breast carcinoma model (tumor growth inhibition ≈100%, increase in lifespan 90.6-114.3%). In P388 lymphocytic leukemia and LLC lung carcinoma, advantages of the protected doxorubicin by the benefit/risk ratio (width of therapeutic interval) were demonstrated: Caelyx>Doxorubicin-NPh>Doxorubicin-Teva. Doxorubicin-NPh and Caelyx exhibited similar therapeutic activity in the LLC model, especially when administered 3 times with 3-day intervals; for Doxorubicin-Teva, the optimal interval between the injections was 7 days.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Malignant Neoplasms in Russia in 2017 (Morbidity and Mortality). Kaprin AD, Starinskii VV, Petrova GV, eds. Moscow, 2018. Russian.

  2. Medvedeva NV, Torkhovskaya TI, Kostryukova LV, Zakharova TS, Kudinov VA, Kasatkina EO, Prozorovskiy VN, Ipatova OM. Influence of doxorubicin inclusion into phospholipid nanoparticles on tumor accumulation and specific activity. Biomed. Khimiya. 2017;63(1):56-61. Russian.

    CAS  Google Scholar 

  3. Archakov AI, Ipatova OM, Medvedeva NV, Prozorovskij VN, Torkhovskaja TI, Tikhonova EG, Zykova MG, Voskresenskaja AA. Patent Ru No. 2411935. Pharmaceutical composition based on doxorubicine and phospholipid nanoparticles for treatment of oncologic diseases. Bull. No. 5. Published February 20, 2011.

  4. Handbook of Cancer Chemotherapy. Skeel RT, ed. Moscow, 2011. Russian.

  5. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19(1):27-39. https://doi.org/10.1016/S1470-2045(17)30777-5

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. P. A. Hertsen Moscow Oncology Research Institute — Branch of National Medical Research Center of Radiology, Ministry of Health of the Russian Federation, Moscow, Russia

    E. R. Nemtsova, O. A. Bezborodova, A. A. Pankratov & J. B. Venediktova

  2. V. N. Orekhovich Research Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia

    E. G. Tikhonova, E. I. Korotkevich, L. V. Kostryukova & J. A. Tereshkina

Authors
  1. E. R. Nemtsova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. G. Tikhonova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. O. A. Bezborodova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. A. Pankratov
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. B. Venediktova
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. I. Korotkevich
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L. V. Kostryukova
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. A. Tereshkina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. R. Nemtsova.

Additional information

Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 169, No. 6, pp. 720-726, June, 2020

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nemtsova, E.R., Tikhonova, E.G., Bezborodova, O.A. et al. Preclinical Study of Pharmacological Properties of Doxorubicin-NPh. Bull Exp Biol Med 169, 778–782 (2020). https://doi.org/10.1007/s10517-020-04977-5

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10517-020-04977-5

Key Words

Search

Navigation